Patient-reported outcomes can be critically important, said Justin Bachmann, MD, MPH, FACC, instructor of Medicine and Health Policy at Vanderbilt University Medical Center.
Patient-reported outcomes can be critically important, said Justin Bachmann, MD, MPH, FACC, instructor of Medicine and Health Policy at Vanderbilt University Medical Center.
Transcript
What is the importance of patient-reported outcomes in cardiology and how can they be better incorporated into payment models?
I think, I’m a little bit biased because a do a little research in this area, but I think patient-reported outcomes are critically important certainly to cardiologists and medicine at large. Patient-reported outcomes focus on what is important to patients, outcomes that matter to patients, what is the patient’s quality of life, how are they feeling, how functional are patients, how much time can they spend with their families. These are things that are critically important above and beyond traditional outcomes such as mortality and readmissions.
We have some very good ones in cardiology. We have PROMs, patient-reported outcome measures, that have been developed by John Spertus, MD, MPH, who is really one of the fathers of patient-reported outcome measures from Kansas City. John developed the Kansas City Cardiomyopathy Questionnaire and the Seattle Angina Questionnaire. These are questionnaires that are highly predictive of mortality and readmissions and also measure quality of life. These are measures that very easily integrated into any kind of value-measured program.
Other PROMs are being developed to focus on conditions such as atrial fibrillation and you start combining those with more general measures of quality of life and NIH [National Institutes of Health] is are developing some of these. They’re called the PROMIS measures. You really have the underpinnings of a very robust measuring system.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More